Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for GeneDx Holdings Corp. (WGS : NSDQ)
 
 • Company Description   
GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn.

Number of Employees: 1,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $82.56 Daily Weekly Monthly
20 Day Moving Average: 920,301 shares
Shares Outstanding: 28.53 (millions)
Market Capitalization: $2,355.70 (millions)
Beta: 2.01
52 Week High: $117.75
52 Week Low: $25.32
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 27.86% 22.08%
12 Week -13.52% -27.02%
Year To Date 7.42% 0.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
333 Ludlow Street North Tower 6th Floor
-
Stamford,CT 06902
USA
ph: 888-729-1206
fax: -
investors@genedx.com http://www.genedx.com
 
 • General Corporate Information   
Officers
Katherine Stueland - Chief Executive Officer and Director
Jason Ryan - Chairman
Kevin Feeley - Chief Financial Officer
Eli D. Casdin - Director
Emily Leproust - Director

Peer Information
GeneDx Holdings Corp. (CHCR)
GeneDx Holdings Corp. (ESRX)
GeneDx Holdings Corp. (MYDP)
GeneDx Holdings Corp. (COR)
GeneDx Holdings Corp. (GBCS)
GeneDx Holdings Corp. (LAXAF)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Medical Services
Sector: Medical
CUSIP: 81663L200
SIC: 8000
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/29/25
Share - Related Items
Shares Outstanding: 28.53
Most Recent Split Date: 5.00 (0.03:1)
Beta: 2.01
Market Capitalization: $2,355.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.29 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.00 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/29/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 82.97
Trailing 12 Months: 90.72
PEG Ratio: -
Price Ratios
Price/Book: 9.15
Price/Cash Flow: 80.68
Price / Sales: 7.14
EPS Growth
vs. Year Ago Period: 184.85%
vs. Previous Quarter: -60.00%
Sales Growth
vs. Year Ago Period: 39.56%
vs. Previous Quarter: -8.91%
ROE
06/30/25 - -
03/31/25 - 10.17
12/31/24 - 3.16
ROA
06/30/25 - -
03/31/25 - 5.51
12/31/24 - 1.67
Current Ratio
06/30/25 - -
03/31/25 - 3.25
12/31/24 - 3.61
Quick Ratio
06/30/25 - -
03/31/25 - 3.07
12/31/24 - 3.42
Operating Margin
06/30/25 - -
03/31/25 - 6.94
12/31/24 - 2.20
Net Margin
06/30/25 - -
03/31/25 - -11.69
12/31/24 - -17.12
Pre-Tax Margin
06/30/25 - -
03/31/25 - -11.63
12/31/24 - -17.23
Book Value
06/30/25 - -
03/31/25 - 9.02
12/31/24 - 8.75
Inventory Turnover
06/30/25 - -
03/31/25 - 10.33
12/31/24 - 10.24
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.20
12/31/24 - 0.21
Debt-to-Capital
06/30/25 - -
03/31/25 - 16.75
12/31/24 - 17.47
 

Powered by Zacks Investment Research ©